Clinical trials: Fusion of Joint
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the efficacy and safety of ixekizumab in Chinese participants with radiographic axial spondyloarthritis (r-axSpA).
- Trial name
- NCT04285229
- Testing
- Ixekizumab
- Where
- 19 sites in China
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Ankylosing Spondylitis
Safety and Efficacy Study of Prefilled Liquid Etanercept(Yisaipu) for Active Ankylosing Spondylitis
This randomized, double-blind, phase III parallel-group non-inferiority study aimed to investigate the efficacy and safety of prefilled liquid etanercept (Yisaipu) versus lyophilized etanercept powder (Yisaipu) in active…
- Trial name
- NCT04345458
- Testing
- prefilled liquid etanercept(Yisaipu), lyophilized etanercept powder(Yisaipu)
- Where
- China
- Volunteers
- 640 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Ankylosing Spondylitis
A Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis
To evaluate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with active ankylosing spondylitis
- Trial name
- NCT00667355
- Testing
- adalimumab
- Where
- 19 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Abbott
Ankylosing Spondylitis
Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis
This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.
- Trial name
- NCT01786668
- Testing
- Tofacitinib 2 mg, Tofacitinib 5 mg, Tofacitinib 10 mg
- Where
- 67 sites in United States, Canada and 8 more
- Volunteers
- 208 people
- Sponsor
- Pfizer
Ankylosing Spondylitis
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
The primary objective of this study was to determine the long-term safety of etanercept in adults with AS who had completed study 0881A3-311-EU.
- Trial name
- NCT00421980
- Testing
- Etanercept
- Where
- Belgium
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ankylosing Spondylitis
A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis
The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis. The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the…
- Trial name
- AS (NCT07237568)
- Testing
- LNK01001
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Non-radiographic Axial Spondyloarthritis
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
This study will establish whether prolonged chronic dosing with secukinumab is needed in participants with Non-radiographic axial spondyloarthritis, (nr-axSpA) who have achieved remission.
- Trial name
- NCT05622708
- Testing
- Secukinumab
- Where
- 61 sites in Belgium, Brazil and 16 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Spondylitis, Ankylosing
Observational Non-Interventional Study With Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
This observational study will be a documentation of the prescribing and administration practices of Enbrel® and their impact on ankylosing spondylitis patients outcome in a real life setting.
- Trial name
- NCT01188655
- Testing
- Enbrel
- Volunteers
- 89 people
- Sponsor
- Pfizer
Joint Disease
Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts
MPO is conducting this PMCF study to evaluate the safety and efficacy of its EVOLUTION® Total Knee Arthroplasty (TKA) components marketed in the EU.
- Trial name
- AMETHYST (NCT02351414)
- Testing
- Total Knee Arthroplasty (EVOLUTION®)
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 150 people
- Sponsor
- MicroPort Orthopedics Inc.
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing components marketed in the European Union (EU).
- Trial name
- NCT02314611
- Testing
- PROFEMUR® Gladiator HA Coated Modular Femoral Stem
- Where
- Belgium
- Volunteers
- 154 people
- Sponsor
- MicroPort Orthopedics Inc.
Axial Spondyloarthritis
AScalate: Treat-to-target in Axial Spondyloarthritis
This was a randomized, parallel-group, open-label, multicenter study in patients with active axSpA. The aim of the study was to demonstrate that the efficacy of a T2T approach (with secukinumab as a first-line biologic) was…
- Trial name
- AScalate (NCT03906136)
- Testing
- Secukinumab/Adalimumab-Biosimilar, Standard-of-care
- Where
- 47 sites in France, Germany
- Volunteers
- 304 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of SPY072 in Rheumatic Disease
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
- Trial name
- SKYWAY-RD (NCT07148414)
- Testing
- SPY002-072
- Where
- 64 sites in United States, Bulgaria and 6 more
- Volunteers
- 285 people
- Sponsor
- Spyre Therapeutics, Inc.
Spondyloarthritis
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
The main purpose of this study is to evaluate the safety and efficacy of the study drug known as ixekizumab in biological disease-modifying anti-rheumatic drugs (bDMARDs)-naive participants with radiographic axial…
- Trial name
- COAST-V (NCT02696785)
- Testing
- Ixekizumab, Adalimumab
- Where
- 28 sites in United States, Czechia and 5 more
- Volunteers
- 341 people
- Sponsor
- Eli Lilly and Company
Arthritis, Rheumatoid, Arthritis, Psoriatic
Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects
The 13G01 clinical trial is a Phase I/II dose escalation study designed to be conducted in adults with inflammatory arthritis who have persistent moderate or severe swelling in one or more joints, without a disease severe enough…
- Conditions
- Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
- Trial name
- NCT00126724
- Testing
- tgAAC94 gene therapy vector
- Where
- 22 sites in United States
- Volunteers
- 120 people
- Sponsor
- Targeted Genetics Corporation
AS
Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis
Study of the efficacy and safety of IBI303 compared with adalimumab in adult patients with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal anti-inflammatory…
- Trial name
- NCT02893254
- Testing
- IBI303, Adalimumab
- Volunteers
- 438 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ankylosing Spondylitis
Safety and Tolerance of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in Patients With Ankylosing Spondylitis
The goal of this clinical trial is to evaluate the safety and tolerability of multiple doses of human umbilical cord mesenchymal stem cell injection in patients with Ankylosing Spondylitis, and to further explore the efficacy…
- Trial name
- NCT05962762
- Testing
- Human Umbilical Cord Mesenchymal Stem Cells
- Volunteers
- 9 people
- Sponsor
- Asia Cell Therapeutics (Shanghai) Co., Ltd.
Fracture;Pelvis, Sacral Fracture
Sacral Fracture Fusion/Fixation for Rapid Rehabilitation
To determine the safety and efficacy of concomitant sacral fracture fixation and sacroiliac (SI) joint fusion vs. non-surgical management for patients with debilitating sacral fragility or insufficiency fractures
- Conditions
- Fracture;Pelvis, Sacral Fracture, Sacroiliac; Fusion, Fragility Fracture
- Trial name
- SAFFRON (NCT05426356)
- Testing
- Surgical Intervention, Non-Surgical Management
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- SI-BONE, Inc.
Fracture; Pelvic, Insufficiency Fractures
Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures
The purpose of this study is to evaluate outcomes in patients treated with iFuse TORQ TNT for pelvic fragility fractures.
- Conditions
- Fracture; Pelvic, Insufficiency Fractures, Fragility Fracture, Sacroiliac; Fusion
- Trial name
- REBAR (NCT07530497)
- Testing
- iFuse TORQ TNT Implant System
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- SI-BONE, Inc.
Ankylosing Spondylitis
Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis
The objective of this study was to evaluate the safety and efficacy of adalimumab 40 mg given every other week (eow) in subjects with active ankylosing spondylitis (AS) who have had an inadequate response to, or who are…
- Trial name
- ATLAS (NCT00085644)
- Testing
- adalimumab (D2E7)
- Where
- 22 sites in United States
- Volunteers
- 315 people
- Sponsor
- Abbott